These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24817793)

  • 1. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals.
    Marques C; Mega C; Gonçalves A; Rodrigues-Santos P; Teixeira-Lemos E; Teixeira F; Fontes-Ribeiro C; Reis F; Fernandes R
    Mediators Inflamm; 2014; 2014():538737. PubMed ID: 24817793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model.
    Gonçalves A; Leal E; Paiva A; Teixeira Lemos E; Teixeira F; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
    Diabetes Obes Metab; 2012 May; 14(5):454-63. PubMed ID: 22151893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
    Gonçalves A; Marques C; Leal E; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
    Biochim Biophys Acta; 2014 Sep; 1842(9):1454-63. PubMed ID: 24769045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
    Mega C; de Lemos ET; Vala H; Fernandes R; Oliveira J; Mascarenhas-Melo F; Teixeira F; Reis F
    Exp Diabetes Res; 2011; 2011():162092. PubMed ID: 22203828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney.
    Joo KW; Kim S; Ahn SY; Chin HJ; Chae DW; Lee J; Han JS; Na KY
    BMC Nephrol; 2013 Apr; 14():98. PubMed ID: 23621921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
    Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
    Vittone F; Liberman A; Vasic D; Ostertag R; Esser M; Walcher D; Ludwig A; Marx N; Burgmaier M
    Diabetologia; 2012 Aug; 55(8):2267-75. PubMed ID: 22648661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats.
    Karabulut S; Coskun ZM; Bolkent S
    Pharmacol Rep; 2015 Oct; 67(5):846-53. PubMed ID: 26398375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties.
    Mega C; Vala H; Rodrigues-Santos P; Oliveira J; Teixeira F; Fernandes R; Reis F; de Lemos ET
    Diabetol Metab Syndr; 2014 Mar; 6(1):42. PubMed ID: 24650557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Zerilli T; Pyon EY
    Clin Ther; 2007 Dec; 29(12):2614-34. PubMed ID: 18201579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes.
    Hernández C; Bogdanov P; Solà-Adell C; Sampedro J; Valeri M; Genís X; Simó-Servat O; García-Ramírez M; Simó R
    Diabetologia; 2017 Nov; 60(11):2285-2298. PubMed ID: 28779212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Petrov A; Eiermann GJ; Woods J; Zhou YP; Li Z; Zycband E; Feng Y; Zhu L; Roy RS; Howard AD; Li C; Thornberry NA; Zhang BB
    Eur J Pharmacol; 2009 Nov; 623(1-3):148-54. PubMed ID: 19765579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
    Kishimoto M; Noda M
    Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats.
    Glorie L; Behets GJ; Baerts L; De Meester I; D'Haese PC; Verhulst A
    Am J Physiol Endocrinol Metab; 2014 Sep; 307(5):E447-55. PubMed ID: 25053403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
    Takai S; Sakonjo H; Jin D
    J Pharmacol Sci; 2014; 125(4):386-93. PubMed ID: 25030743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
    Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
    Satoh-Asahara N; Sasaki Y; Wada H; Tochiya M; Iguchi A; Nakagawachi R; Odori S; Kono S; Hasegawa K; Shimatsu A
    Metabolism; 2013 Mar; 62(3):347-51. PubMed ID: 23062489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).
    Ferreira L; Teixeira-de-Lemos E; Pinto F; Parada B; Mega C; Vala H; Pinto R; Garrido P; Sereno J; Fernandes R; Santos P; Velada I; Melo A; Nunes S; Teixeira F; Reis F
    Mediators Inflamm; 2010; 2010():592760. PubMed ID: 20652060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.